CLINICAL - STAGE COMPETITIVE INTELLIGENCE
Know the field before the field knows your asset.
And the access path before your read-out locks it.
For clinical-stage assets and marketed franchises.
I map the competitive landscape, the real-time signals others miss, and the access criteria your evidence will actually be measured against before the Phase 3 protocol locks, or before the cliff arrives
Built to support evidence strategy, defend-vs-acquire decisions, and replacement planning before the window closes.
15+ years in healthcare commercialization across the US and Europe.
One intelligence engine with multiple lenses: shape the evidence package early, or defend the franchise late.
WHO IT'S FOR
Clinical-stage
For Phase 2 sponsors and the teams backing them.
Shape the competitive landscape, real-time signals, and the access criteria into the Phase 3 protocol before the readout locks it.
Loss of Exclusivity
For franchise leads facing a patent cliff.
Map the three replacement paths : indication expansion, next-asset readiness, partner or acquire with credible candidates, timing, and the competitive pressure that decides which path wins
THE ENGINE
Whether you're shaping a Phase 3 protocol or defending a franchise, the underlying questions are the same. I assemble three layers into one brief, every claim traced to a named source.
Competitive Landscape
Every asset in the indication, mapped by class, mechanism, line of therapy and the access position each one occupies.
Real-time Signals
Independent partner filings. Head-to-head trial designs. Conference late-breakers. The competitive moves that change the landscape between annual market reports.
Access Path
Patient Access Distance - a policy-derived score, reverse-engineered from primary payer and HTA documents. How far the patient sits from the drug, and what evidence shortens that distance.
AUDIENCE
One brief addressing three different rooms
Pharma Strategy
Portfolio gap mapping and defend-vs-acquire framing. Where the next threat enters your franchise, and how much runway you have before it does
Business Development
Target prioritisation and urgency signals. The competitive rationale behind a partnering or licensing decision, ready for the deal team.
Investors
Cliff risk, replacement credibility, and competition timing on the assets in your book - the diligence questions before the term sheet.
ABOUT
15+ years in healthcare commercialization and enterprise integration across the US and Europe. Pharma commercial operations, medical device and EHR integration, and go-to-market execution. MBA, Chicago Booth.
I started building this because the tools franchise leads and clinical-stage teams rely on answer the wrong question. They count and list trials and patents. They don't tell you whether your evidence will satisfy the criteria the access decision actually turns on.
Currently taking on a small number of pilot partners - clinical-stage sponsors, franchise teams, and the consultancies that serve them.